← TrialMatch
HomeTrials

Effect of Transcranial Magnetic Stimulation on Visual Functions of Adult Amblyopia: a Prel

Amblyopia, with a prevalence rates of 3% in adult population, is a common cause of vision impairment. It is characterized by impaired vision in one or both eyes because of disruption of normal visual stimuli and underdevelopment of the visual cortex, leads to lifelong visual deficits affecting both monocular and binocu

Condition(s)Amblyopia
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryAmblyopia, with a prevalence rates of 3% in adult population, is a common cause of vision impairment. It is characterized by impaired vision in one or both eyes because of disruption of normal visual stimuli and underdevelopment of the visual cortex, leads to lifelong visual deficits affecting both monocular and binocular visual function. Common causes of amblyopia include refraction error, anisometropia, strabismus and visual deprivation arising from ptosis or congenital cataract. Our previous studies had shed light on the relationship between abnormal early visual experience, and development of later amblyopia and possible neural developmental disorders. Functional recovery is difficult when neuroplasticity slows down at the end of the critical period. To date, there is no established ef
Who can participateInclusion Criteria: 1. Adult amblyopia participants, aged 20-50 years old. 2. Based on inclusion criteria, there was a minimum of 2 lines difference in BCVA between the 2 eyes. 3. An amblyogenic factor and history of amblyopia treatment was recorded Exclusion Criteria: 1. Unstable vital sign 2. History of brain injury and/or head trauma 3. Neurological and psychiatric disease 4. Seizures or family history of seizure 5. Pregnancy 6. Uncontrolled migraine or the presence of metallic implants or shunt in the head or torso 7. Wide region of ischemic cicatrix, multiple sclerosis, taking tricycle antidepressants, 8. Analgesics or any drugs may decrease the threshold for inducing seizure 9. Experienced sleep disorders during the rTMS treatment 10. Severe alcoholism or taking seizure drugs 11. Sev
Ages20 Years to 50 Years
SexAll
Lead sponsorNational Taiwan University Hospital
LocationsTaipei County, Taiwan
Start date2023-01-05
NCT IDNCT05393739
Official listinghttps://clinicaltrials.gov/study/NCT05393739

🔍 Search all trials →